-
1
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
Levy, R.S.4
Gupta, V.5
DiPersio, J.F.6
Catalano, J.V.7
Deininger, M.8
Miller, C.9
Silver, R.T.10
Talpaz, M.11
Winton, E.F.12
Harvey Jr., J.H.13
Arcasoy, M.O.14
Hexner, E.15
Lyons, R.M.16
Paquette, R.17
Raza, A.18
Vaddi, K.19
Erickson-Viitanen, S.20
Koumenis, I.L.21
Sun, W.22
Sandor, V.23
Kantarjian, H.M.24
more..
-
2
-
-
79551478191
-
Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: Performance in 86 myelofibrosis patients on INCB018424 clinical trial
-
Mesa RA, Kantarjian H, Tefferi A, et al. Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. Blood. 2009;114:3917-3917.
-
(2009)
Blood
, vol.114
, pp. 3917-3917
-
-
Mesa, R.A.1
Kantarjian, H.2
Tefferi, A.3
-
3
-
-
79551478191
-
Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: Performance in 86 myelofibrosis patients on INCB018424 clinical trial
-
Mesa RA, Kantarjian H, Tefferi A, et al. Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. Blood. 2009;114:3917-3917.
-
(2009)
Blood
, vol.114
, pp. 3917-3917
-
-
Mesa, R.A.1
Kantarjian, H.2
Tefferi, A.3
-
4
-
-
84893504789
-
New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment
-
Nov 20. [Epub ahead of print]
-
Basch E. New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment. Annu Rev Med. 2013 Nov 20. [Epub ahead of print].
-
(2013)
Annu Rev Med
-
-
Basch, E.1
-
6
-
-
84874371892
-
Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension
-
CONSORT PRO Group
-
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-22.
-
(2013)
JAMA
, vol.309
, Issue.8
, pp. 814-822
-
-
Calvert, M.1
Blazeby, J.2
Altman, D.G.3
Revicki, D.A.4
Moher, D.5
Brundage, M.D.6
-
7
-
-
84880222871
-
-
National Quality Forum January 10, Avai lable at: last accessed 4/26/14
-
National Quality Forum. Patient-reported outcomes (PROs) in performance measurement. January 10, 2013. Avai lable at: www.qualityforum.org/Projects/n-r/ Patient-Reported-Outcomes/Patient-Reported-Outcomes.aspx, last accessed 4/26/14.
-
(2013)
Patient-reported Outcomes (PROs) in Performance Measurement
-
-
-
8
-
-
84880166205
-
Patient-reported outcomes-based performance measures
-
Basch E, Torda P, Adams K. Patient-reported outcomes-based performance measures. JAMA. 2013;310(2):139-40.
-
(2013)
JAMA
, vol.310
, Issue.2
, pp. 139-140
-
-
Basch, E.1
Torda, P.2
Adams, K.3
-
9
-
-
84885176452
-
Patient-reported outcomes in randomized clinical trials: Development of ISOQOL reporting standards
-
Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, Efficace F, King M, Lam CL, Moher D, Scott J, Sloan J, Snyder C, Yount S, Calvert M. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22(6):1161-75.
-
(2013)
Qual Life Res
, vol.22
, Issue.6
, pp. 1161-1175
-
-
Brundage, M.1
Blazeby, J.2
Revicki, D.3
Bass, B.4
De Vet, H.5
Duffy, H.6
Efficace, F.7
King, M.8
Lam, C.L.9
Moher, D.10
Scott, J.11
Sloan, J.12
Snyder, C.13
Yount, S.14
Calvert, M.15
-
10
-
-
84877056690
-
-
last accessed 4/26/14
-
International Society for Pharmacoeconomics and Outcomes Research. ISPOR Good Practices for Outcomes Research Index. http://www.ispor.org/workpaper/ practices-index.asp, last accessed 4/26/14.
-
ISPOR Good Practices for Outcomes Research Index
-
-
-
11
-
-
84861163178
-
A review of patient-reported outcome labels in the United States: 2006 to 2010
-
Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012;15(3):437-42.
-
(2012)
Value Health
, vol.15
, Issue.3
, pp. 437-442
-
-
Gnanasakthy, A.1
Mordin, M.2
Clark, M.3
DeMuro, C.4
Fehnel, S.5
Copley-Merriman, C.6
-
12
-
-
79960259603
-
Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers
-
Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J, Wilkinson A, Feldman-Stewart D. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011;20(5):653-64.
-
(2011)
Qual Life Res
, vol.20
, Issue.5
, pp. 653-664
-
-
Brundage, M.1
Bass, B.2
Davidson, J.3
Queenan, J.4
Bezjak, A.5
Ringash, J.6
Wilkinson, A.7
Feldman-Stewart, D.8
-
13
-
-
84905899988
-
Addressing Content Validity of PRO Measures: The Unique Case of Rare Diseases
-
http://www.ispor.org/workpaper/practices-index.asp last accessed 4/26/14
-
Leidy, N.K. Addressing Content Validity of PRO Measures: The Unique Case of Rare Diseases. EveryLife Foundation, Workshop 2: Clinical Evaluation of Rare Disease Treatments. June 14 -15, 2011, Washington DC. http://www. everylifefoundation.org/wp-content/uploads/images/workshopseries/ 13-Leidy-Addressing-Content-Validity-of-PROS802Measures.pdf, http://www.ispor.org/workpaper/practices-index.asp, last accessed 4/26/14.
-
Workshop 2: Clinical Evaluation of Rare Disease Treatments. June 14 -15, 2011, Washington DC
-
-
Leidy, N.K.1
-
15
-
-
84879406265
-
Pediatric patient-reported outcome instruments for research to support medical product labeling: Report of the ISPOR PRO good research practices for the assessment of children and adolescents task force
-
Matza LS, Patrick D, Riley AW, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: Report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16:461-79.
-
(2013)
Value Health
, vol.16
, pp. 461-479
-
-
Matza, L.S.1
Patrick, D.2
Riley, A.W.3
|